Achieving complete metabolic response in stage IV lung adenocarcinoma with chemotherapy, nivolumab, ipilimumab, and salvage SBRT: A case report
Open Access
- 24 April 2024
- journal article
- research article
- Published by Wiley in Respirology Case Reports
- Vol. 12 (4) , e01362
Abstract
Oncogene‐negative, PDL1‐negative metastatic non‐small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55‐year‐old male patient with oncogene‐negative, PDL1‐negative stage IV lung adenocarcinoma, showcasing an exceptional complete metabolic response to a multimodality treatment combining double immune checkpoint inhibition (ICI) and chemotherapy, followed by salvage stereotactic body radiotherapy (SBRT). The patient underwent a treatment regimen incorporating two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab followed by nivolumab, and ipilimumab maintenance. After a partial response, SBRT was applied to persistent lesions, achieving a complete metabolic response. This case highlights the potential of combining dual ICI with chemotherapy and SBRT in treating oncogene‐negative, PDL1‐negative NSCLC underscoring the importance of multimodality treatment strategies.Keywords
This publication has 5 references indexed in Scilit:
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- First-Line Immunotherapy for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2022
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challengesJournal of Hematology & Oncology, 2020
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialJournal of Clinical Oncology, 2020